LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy
Public ClinicalTrials.gov record NCT01345669. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomised, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Afatinib (BIBW 2992) as Adjuvant Therapy After Chemo-radiotherapy in Primary Unresected Patients With Stage III, IVa, or IVb Loco-regionally Advanced Head and Neck Squamous Cell Carcinoma
Study identification
- NCT ID
- NCT01345669
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Enrollment
- 617 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- Afatinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 16, 2011
- Primary completion
- Sep 11, 2016
- Completion
- Sep 11, 2016
- Last update posted
- Dec 6, 2017
2011 – 2016
United States locations
- U.S. sites
- 15
- U.S. states
- 13
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1200.131.00171 Boehringer Ingelheim Investigational Site | Little Rock | Arkansas | — | — |
| 1200.131.00181 Boehringer Ingelheim Investigational Site | Orange | California | — | — |
| 1200.131.00177 Boehringer Ingelheim Investigational Site | Aurora | Colorado | — | — |
| 1200.131.00185 Boehringer Ingelheim Investigational Site | New Haven | Connecticut | — | — |
| 1200.131.00173 Boehringer Ingelheim Investigational Site | Baltimore | Maryland | — | — |
| 1200.131.00176 Boehringer Ingelheim Investigational Site | Boston | Massachusetts | — | — |
| 1200.131.00182 Boehringer Ingelheim Investigational Site | Omaha | Nebraska | — | — |
| 1200.131.00175 Boehringer Ingelheim Investigational Site | Lebanon | New Hampshire | — | — |
| 1200.131.00179 Boehringer Ingelheim Investigational Site | Stony Brook | New York | — | — |
| 1200.131.00188 Boehringer Ingelheim Investigational Site | The Bronx | New York | — | — |
| 1200.131.10200 Boehringer Ingelheim Investigational Site | Winston-Salem | North Carolina | — | — |
| 1200.131.00172 Boehringer Ingelheim Investigational Site | Philadelphia | Pennsylvania | — | — |
| 1200.131.00184 Boehringer Ingelheim Investigational Site | San Antonio | Texas | — | — |
| 1200.131.00198 Boehringer Ingelheim Investigational Site | Spokane Valley | Washington | — | — |
| 1200.131.00183 Boehringer Ingelheim Investigational Site | Wenatchee | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 147 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01345669, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 6, 2017 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01345669 live on ClinicalTrials.gov.